According to a paper published in Nature, a personalized cancer vaccine using the mRNA platform showed positive results in a Phase 2 clinical trial.
In an experiment targeting melanoma patients, it reduced the recurrence rate by 44% compared to existing immunotherapy. Although it has not yet been approved, the potential of the technology seems significant. Related research is also underway in Korea, but we'll have to wait and see.